BioSpace News Archive

Ikena Oncology, Inc. today announced financial results for the second quarter ended June 30, 2022.

Homology Medicines, Inc., a genetic medicines company, announced the details of HMI-204, its optimized, in vivo, one-time gene therapy product candidate for the treatment of metachromatic leukodystrophy.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, reported financial results for the second quarter ended June 30, 2022.

Context Therapeutics Inc., a women’s oncology company developing novel treatments for breast and gynecological cancers, announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.

ResMed Inc. announced results for its quarter ended June 30, 2022.

NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2022.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2022 financial results.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update.